-DOCSTART- -X- O
Newcastle -X- _ O
disease -X- _ O
( -X- _ O
ND -X- _ O
) -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
important -X- _ O
diseases -X- _ O
of -X- _ O
poultry -X- _ O
worldwide. -X- _ O
In -X- _ O
the -X- _ O
last -X- _ O
decades -X- _ O
, -X- _ O
molecular -X- _ O
research -X- _ O
has -X- _ O
gained -X- _ O
a -X- _ O
lot -X- _ O
of -X- _ O
new -X- _ O
information -X- _ O
about -X- _ O
its -X- _ O
causative -X- _ O
agent -X- _ O
, -X- _ O
newcastle -X- _ B-Intervention
disease -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
NDV -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
In -X- _ O
poultry -X- _ B-Patient
industry -X- _ I-Patient
, -X- _ O
certain -X- _ O
strains -X- _ O
of -X- _ O
NDV -X- _ O
have -X- _ O
been -X- _ O
used -X- _ O
for -X- _ O
preventive -X- _ O
vaccination -X- _ O
for -X- _ O
more -X- _ O
than -X- _ O
60 -X- _ O
years. -X- _ O
NDV -X- _ O
has -X- _ O
also -X- _ O
been -X- _ O
applied -X- _ O
to -X- _ O
cancer -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ O
beneficial -X- _ B-Outcome
effects -X- _ I-Outcome
for -X- _ I-Outcome
about -X- _ I-Outcome
50 -X- _ I-Outcome
years -X- _ I-Outcome
, -X- _ O
but -X- _ O
this -X- _ O
is -X- _ O
less -X- _ O
well -X- _ O
known. -X- _ O
The -X- _ O
molecular -X- _ O
basis -X- _ O
for -X- _ O
these -X- _ O
differential -X- _ O
effects -X- _ O
of -X- _ O
NDV -X- _ O
in -X- _ O
birds -X- _ O
and -X- _ O
man -X- _ O
have -X- _ O
been -X- _ O
elucidated -X- _ O
in -X- _ O
the -X- _ O
last -X- _ O
decades -X- _ O
and -X- _ O
are -X- _ O
explained -X- _ O
in -X- _ O
this -X- _ O
review. -X- _ O
The -X- _ O
anti-neoplastic -X- _ B-Outcome
and -X- _ I-Outcome
immune-stimulatory -X- _ I-Outcome
properties -X- _ I-Outcome
in -X- _ O
non-permissive -X- _ O
hosts -X- _ O
such -X- _ O
as -X- _ O
mouse -X- _ O
and -X- _ O
man -X- _ O
have -X- _ O
to -X- _ O
do -X- _ O
with -X- _ O
the -X- _ O
strong -X- _ B-Intervention
type -X- _ I-Intervention
I -X- _ I-Intervention
interferon -X- _ I-Intervention
responses -X- _ I-Intervention
induced -X- _ O
in -X- _ O
these -X- _ O
foreign -X- _ O
species. -X- _ O
Additionally -X- _ O
, -X- _ O
NDV -X- _ O
has -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
break -X- _ O
various -X- _ O
types -X- _ O
of -X- _ O
tumor -X- _ O
resistances -X- _ O
and -X- _ O
also -X- _ O
to -X- _ O
affect -X- _ O
liver -X- _ O
fibrosis. -X- _ O
A -X- _ O
main -X- _ O
section -X- _ O
is -X- _ O
devoted -X- _ O
to -X- _ O
the -X- _ O
benefits -X- _ O
of -X- _ O
clinical -X- _ O
application -X- _ O
of -X- _ O
NDV -X- _ O
and -X- _ O
NDV-based -X- _ B-Intervention
vaccines -X- _ I-Intervention
to -X- _ O
cancer -X- _ B-Patient
patients. -X- _ I-Patient
Reverse -X- _ B-Outcome
genetics -X- _ I-Outcome
technology -X- _ I-Outcome
allowed -X- _ I-Outcome
developing -X- _ I-Outcome
NDV -X- _ I-Outcome
into -X- _ I-Outcome
a -X- _ I-Outcome
vector -X- _ I-Outcome
suitable -X- _ I-Outcome
for -X- _ I-Outcome
gene -X- _ I-Outcome
therapy. -X- _ I-Outcome
Examples -X- _ O
will -X- _ O
be -X- _ O
provided -X- _ O
in -X- _ O
which -X- _ O
genetically -X- _ O
engineered -X- _ O
NDV -X- _ O
is -X- _ O
being -X- _ O
used -X- _ O
successfully -X- _ O
as -X- _ O
vector -X- _ O
against -X- _ O
new -X- _ O
emerging -X- _ O
viruses -X- _ O
. -X- _ O

